乳腺癌多药耐药与Her-2基因表达的相关性研究

Correlation between multi-drug resisitance and Her-2 gene in breast cancer

目的探讨乳腺癌组织中P-糖蛋白（p170）、胚胎型谷胱甘肽-S-转移酶-π（GST-π）和DNA拓扑异构酶Ⅱ（TOPOⅡ）与人类表皮生长因子受体2（Her-2）表达的相关l生和临床意义。方法乳腺癌标本48例。采用荧光原位杂交法（FISH）检测Her-2的表达，采用免疫组织化学sP法检测乳腺癌石蜡标本中p170、GST-π、TOPOⅡ的表达，分析p170、GST、TOPOⅡ与临床病理因素的关系及与Her-2的相关性。结果乳腺癌组织中，p170、GST-π、TOPOⅡ阳性表达率分别为43．8％（21／48）、39．6％（19／48）、56．3％（27／48）。p170、GST-π、TOPOⅡ表达在不同年龄、不同肿瘤大小、是否淋巴结转移患者间差异无统计学意义（P〉0．05）。p170、GST-π、TOPOⅡ表达与Hel-2表达呈正相关（P〈0．05）。结论p170、GST-π、TOPOⅡ表达与Her-2相关，均可作为临床上检测及指导治疗的重要指标。

Objective To investigate the correlation between the expression of pl70,GST-π ,TOPO Ⅱ and the expression of Her-2 in human breast cancer. Methods The expression of Her-2 was detected by fluorescence in situ hybridization. The expression of pl70, GST-π, TOPO Ⅱ were tested in 48 breast cancer by immunohistochemical SP method, and their correlations with elinicopathological features and the expression of Her-2 were analyzed. Results The positive rate of pl70, GST-π, TOPO Ⅱ were 43.8 %（21/48）, 39.6 %（19/ 48）, 56.3 %（27/48）, respectively. The expression of p170, GST-π, TOPOⅡ positively correlated with the expression of Her-2（P 〈 0.05）. The levels of p170, GST-π, TOPO Ⅱ expression were not associated with age, primary tumor and lymph node metastasis（P 〉 0.05）. Conclusion There is great possibility of chemotherapy drug resistance in breast cancer with expression of Her-2. Expressions of p170, GST-π, TOPO Ⅱ and Her-2 have an instructive significance for chemotherapy.